The relationship between late lumen loss and restenosis among various drug-eluting stents: A systematic review and meta-regression analysis of randomized clinical trials

Atherosclerosis

Volumn 214, Issue 1, 2011, Pages 158-162

  Brener, Sorin J ^a   Prasad, Ashok J ^a   Khan, Zubair ^a   Sacchi, Terrence J ^a  

^a NEW YORK METHODIST HOSPITAL   (United States)

Author keywords

DES, Restenosis, QCA

Indexed keywords

BIOLIMUS; EVEROLIMUS; LACTONE; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANGIOGRAPHY; ARTICLE; BLOOD VESSEL DIAMETER; DIABETES MELLITUS; DRUG ELUTING STENT; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SYSTEMATIC REVIEW;

AGED; ANGIOGRAPHY; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SIROLIMUS;

EID: 78650843980     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.046     Document Type: Article

References (38)

1. Tu J.V., Bowen J., Chiu M., et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007, 357(14):1393-1402.
2. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356(10):998-1008.
3. Mauri L., Orav E.J., Candia S.C., Cutlip D.E., Kuntz R.E. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005, 112(18):2833-2839.
4. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005, 353(7):663-670.
5. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005, 293(2):165-171.
6. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005, 353(7):653-662.
7. Cervinka P., Costa M.A., Angiolillo D.J., et al. Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study" Catheter Cardiovasc Interv 2006, 67(6):846-851.
8. Han Y.L., Wang X.Z., Jing Q.M., Wang S.L., Ma Y.Y., Luan B. Comparison of rapamycin and paclitaxel eluting stent in patients with multi-vessel coronary disease. Zhonghua Xin Xue Guan Bing Za Zhi 2006, 34(2):123-126.
9. Kandzari D.E., Leon M.B., Popma J.J., et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006, 48(12):2440-2447.
10. Kim Y.H., Park S.W., Lee S.W., et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006, 114(20):2148-2153.
11. Mehilli J., Dibra A., Kastrati A., et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006, 27(3):260-266.
12. Mehilli J., Kastrati A., Wessely R., et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006, 113(2):273-279.
13. Morice M.C., Colombo A., Meier B., et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006, 295(8):895-904.
14. Serruys P.W., Ruygrok P., Neuzner J., et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention 2006, 2(3):286-294.
15. Adriaenssens T., Mehilli J., Wessely R., et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol 2007, 49(12):1265-1271.
16. Chevalier B., Serruys P.W., Silber S., et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2007, 2(4):426-434.
17. Pan M., Suarez de Lezo J., Medina A., et al. Drug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. Am Heart J 2007, 153(1):15 e1-7.
18. Petronio A.S., De Carlo M., Branchitta G., et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. Am Coll Cardiol 2007, 49(5):539-546.
19. Wessely R., Kastrati A., Mehilli J., et al. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. Eur Heart J 2007, 28(22):2720-2725.
20. Chevalier B., Di Mario C., Neumann F.J., et al. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv 2008, 1(5):524-532.
21. Kereiakes D.J., Petersen J.L., Batchelor W.B., et al. Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. J Invasive Cardiol 2008, 20(7):335-341.
22. Kim M.H., Hong S.J., Cha K.S., et al. Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. J Interv Cardiol 2008, 21(3):225-231.
23. Lee J.H., Kim H.S., Lee S.W., et al. Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. Catheter Cardiovasc Interv 2008, 72(1):25-32.
24. Mehilli J., Byrne R.A., Wieczorek A., et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008, 29(16):1975-1982.
25. Ostojic M., Sagic D., Beleslin B., et al. First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention 2008, 3(5):574-579.
26. Stone G.W., Midei M., Newman W., et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008, 299(16):1903-1913.
27. Windecker S., Serruys P.W., Wandel S., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008, 372(9644):1163-1173.
28. Chevalier B., Silber S., Park S.J., et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial-Phase 2. Circ Cardiovasc Interv 2009, 2(3):188-195.
29. Lee C.W., Park D.W., Lee S.H., et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009, 104(10):1370-1376.
30. Lemos P.A., Moulin B., Perin M.A., et al. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheter Cardiovasc Interv 2009, 74(5):665-673.
31. Mehilli J., Byrne R.A., Tiroch K., et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents the isar-desire 2 (intracoronary stenting and angiographic results: drug eluting stents for in-stent restenosis 2) study. J Am Coll Cardiol 2010.
32. Serruys P.W., Silber S., Garg S., et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010, 363(2):136-146.
33. Tommasini G., Rubartelli P., Piaggio M. A deterministic approach to automated stenosis quantification. Catheter Cardiovasc Interv 1999, 48(4):435-445.
34. Mauri L., Orav E.J., Kuntz R.E. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005, 111(25):3435-3442.
35. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005, 294(7):819-825.
36. Ellis S.G., Popma J.J., Lasala J.M., et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005, 45(8):1193-1200.
37. Pocock S.J., Lansky A.J., Mehran R., et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized controlled trials. J Am Coll Cardiol 2008, 51(1):23-32.
38. Moreno R., Fernandez C., Sanchez-Recalde A., et al. Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J 2007, 28(13):1583-1591.